JP2023540444A - 治療用抗体 - Google Patents

治療用抗体 Download PDF

Info

Publication number
JP2023540444A
JP2023540444A JP2023507798A JP2023507798A JP2023540444A JP 2023540444 A JP2023540444 A JP 2023540444A JP 2023507798 A JP2023507798 A JP 2023507798A JP 2023507798 A JP2023507798 A JP 2023507798A JP 2023540444 A JP2023540444 A JP 2023540444A
Authority
JP
Japan
Prior art keywords
sequence
seq
antibody
sequence identity
ox40l
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540444A5 (enExample
Inventor
アラン・ブラッドリー
アンドリュー・ジェームズ・トンプソン
ダニエル・ジョン・ボーランド
ジュエシュアン・ワン
ロベルト・バンディエラ
スティーヴ・ホームズ
Original Assignee
ペットメディックス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペットメディックス・リミテッド filed Critical ペットメディックス・リミテッド
Publication of JP2023540444A publication Critical patent/JP2023540444A/ja
Publication of JP2023540444A5 publication Critical patent/JP2023540444A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023507798A 2020-08-07 2021-08-06 治療用抗体 Pending JP2023540444A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2012331.1A GB202012331D0 (en) 2020-08-07 2020-08-07 Therapeutic antibodies
GB2012331.1 2020-08-07
PCT/GB2021/052043 WO2022029447A1 (en) 2020-08-07 2021-08-06 Therapeutic antibodies

Publications (2)

Publication Number Publication Date
JP2023540444A true JP2023540444A (ja) 2023-09-25
JP2023540444A5 JP2023540444A5 (enExample) 2026-02-02

Family

ID=72520053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507798A Pending JP2023540444A (ja) 2020-08-07 2021-08-06 治療用抗体

Country Status (8)

Country Link
US (1) US20230272097A1 (enExample)
EP (1) EP4192867A1 (enExample)
JP (1) JP2023540444A (enExample)
CN (1) CN116249710A (enExample)
AU (1) AU2021319941A1 (enExample)
CA (1) CA3186391A1 (enExample)
GB (1) GB202012331D0 (enExample)
WO (1) WO2022029447A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240052871A (ko) 2016-04-27 2024-04-23 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US20220332837A1 (en) * 2021-04-08 2022-10-20 Colorado State University Research Foundation Methods and compositions for ox40 activation in treatment of canine cancer
IL314314A (en) * 2022-02-09 2024-09-01 Petmedix Ltd Therapeutic antibodies
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
AU2023417626A1 (en) 2022-12-27 2025-07-10 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
WO2024155982A2 (en) 2023-01-20 2024-07-25 Invetx, Inc. Bispecific binding agents for use in companion animals
WO2025174998A1 (en) * 2024-02-13 2025-08-21 Invetx, Inc. Anti-il-31ra antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530045A (ja) * 2004-03-23 2007-11-01 アムジエン・インコーポレーテツド ヒトｏｘ４０ｌ（ｃｄ１３４ｌ）特異性モノクローナル抗体
US20170137843A1 (en) * 2012-02-14 2017-05-18 Merial, Inc. Recombinant Poxviral Vectors Expressing both Rabies and OX40 Proteins, and Vaccines Made Therefrom

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US7812133B2 (en) * 2005-12-16 2010-10-12 Genentech, Inc Anti-OX40L antibodies and methods using same
HRP20180858T1 (hr) 2011-07-11 2018-09-21 Glenmark Pharmaceuticals S.A. Protutijela koja se vežu na ox40 i njihove uporabe
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
KR102740384B1 (ko) 2015-03-03 2024-12-06 키맵 리미티드 항체, 용도 및 방법
GB2561352B (en) 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
KR20250026872A (ko) 2018-03-16 2025-02-25 조에티스 서비시즈 엘엘씨 수의학적 용도를 위한 인터류킨-31 단클론성 항체
GB2578867A (en) 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530045A (ja) * 2004-03-23 2007-11-01 アムジエン・インコーポレーテツド ヒトｏｘ４０ｌ（ｃｄ１３４ｌ）特異性モノクローナル抗体
US20170137843A1 (en) * 2012-02-14 2017-05-18 Merial, Inc. Recombinant Poxviral Vectors Expressing both Rabies and OX40 Proteins, and Vaccines Made Therefrom

Also Published As

Publication number Publication date
AU2021319941A1 (en) 2023-02-16
CA3186391A1 (en) 2022-02-10
GB202012331D0 (en) 2020-09-23
WO2022029447A1 (en) 2022-02-10
US20230272097A1 (en) 2023-08-31
CN116249710A (zh) 2023-06-09
EP4192867A1 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
US20230060847A1 (en) Anti-bcma heavy chain-only antibodies
JP6938383B2 (ja) イヌインターロイキン４受容体アルファに対する抗体
JP7303126B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
JP7254699B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
US20230272097A1 (en) Therapeutic antibodies
JP2024020377A (ja) 抗ｃｄ３８抗体および使用方法
CA2861793C (en) Method of providing monoclonal auto-antibodies with desired specificity
US10131709B2 (en) Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
WO2017134292A1 (en) Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
CN117986366A (zh) 拮抗性抗犬pd-1抗体
JP2024530036A (ja) 抗体Ｆｃバリアント
US20200247903A1 (en) Method
US20250340659A1 (en) Therapeutic antibodies
CN118715244A (zh) 治疗性抗体
CN121108346B (zh) 抗ly6g6d单域抗体及其制备方法和用途
WO2026086936A1 (en) Uses of multispecific antigen binding proteins capable of binding cd19 and cd3
CN120842422A (zh) 一种抗CD30和CD16a的双特异性抗体及其应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240802

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251024

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20260123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260324